Bone Health and Bone-Targeted Therapies for Prostate Cancer

Publication Date: February 19, 2020
Last Updated: March 14, 2022

Recommendations

For men with nonmetastatic prostate cancer at high risk of fracture receiving androgen deprivation therapy (ADT), denosumab at the osteoporosis-indicated dosage should be considered to reduce the risk of fracture. In situations or jurisdictions where denosumab is contraindicated or not available, a bisphosphonate is a reasonable option.
6731

Overview

Title

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Authoring Organization

American Society of Clinical Oncology